Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lacidipine (SN-305) 是一种L 型钙离子通道阻断剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 213 | 现货 | ||
10 mg | ¥ 411 | 现货 | ||
25 mg | ¥ 690 | 现货 | ||
50 mg | ¥ 970 | 现货 | ||
100 mg | ¥ 1,523 | 现货 | ||
200 mg | ¥ 2,368 | 现货 | ||
500 mg | ¥ 3,550 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 474 | 现货 |
产品描述 | Lacidipine (SN-305) is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure. |
体外活性 | Lacidipine, an L-type Ca(2+) channel blocker that also inhibits [Ca(2+)](ER) efflux, enhances folding, trafficking, and activity of degradation-prone glucocerebrosidase (GC) variants. Lacidipine remodels mutated GC proteostasis by simultaneously activating a series of distinct molecular mechanisms, namely modulation of Ca(2+) homeostasis, upregulation of the ER chaperone BiP, and moderate induction of the unfolded protein response. [1] Lacidipine almost completely inhibits cholesterol esterification in cholesterol loaded mouse cultured peritoneal macrophages. [2] |
体内活性 | Lacidipine has non-significant effects on blood pressure but inhibits the paradoxical increases in plasma renin activity (PRA) and in renin mRNA in kidney that are found in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP). Lacidipine restores the physiological downregulation of renin production by high salt and reduces left ventricular hypertrophy and mRNA levels of atrial natriuretic factor and transforming growth factor-beta1. [3] Lacidipine (1 and 3 mg/kg) also effectively increases calcium concentrations significantly in ovariectomized rats. [4] Lacidipine, a dihydropyridine-type calcium antagonist, reduces the cardiac hypertrophy and the cardiacendothelin-1 (ET-1) gene overexpression occurring in salt-loaded stroke-prone spontaneously hypertensive rats (SL-SHRSP), an effect occurring without systolic blood pressure (SBP) change. Lacidipine exerts a dose-related inhibition of ventricle hypertrophy and preproET-1-mRNA expression in SHRSP and indicate that this effect is unrelated to SBP changes. [5] |
别名 | SN-305, 拉西地平, GX-1048, GR-43659X |
分子量 | 455.54 |
分子式 | C26H33NO6 |
CAS No. | 103890-78-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 84 mg/mL (184.4 mM)
Ethanol: 21 mg/mL (46.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.1952 mL | 10.976 mL | 21.952 mL | 54.8799 mL |
5 mM | 0.439 mL | 2.1952 mL | 4.3904 mL | 10.976 mL | |
10 mM | 0.2195 mL | 1.0976 mL | 2.1952 mL | 5.488 mL | |
20 mM | 0.1098 mL | 0.5488 mL | 1.0976 mL | 2.744 mL | |
DMSO | 50 mM | 0.0439 mL | 0.2195 mL | 0.439 mL | 1.0976 mL |
100 mM | 0.022 mL | 0.1098 mL | 0.2195 mL | 0.5488 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lacidipine 103890-78-4 Apoptosis Immunology/Inflammation Membrane transporter/Ion channel Metabolism NF-Κb Reactive Oxygen Species Calcium Channel SN-305 inhibit 拉西地平 Ca2+ channels hypertension SN 305 GX 1048 Inhibitor SN305 GX-1048 HKC cells GR-43659X Ca channels AKI Caspase atherosclerosis GX1048 inhibitor